摘要
目的:探讨复方丹参滴丸联合阿托伐他汀治疗冠心病并高脂血症的疗效及对血清肿瘤坏死因子相关凋亡诱导配体(TRAIL)的影响。方法:收集我院的冠心病合并高脂血症患者109例。随机分为阿托伐他汀组(57例)和联合治疗组(52例,阿托伐他汀联合复方丹参滴丸治疗),疗程3个月,检测治疗前后的心功能、血脂、血清肿瘤坏死因子(TNF-α)、TRAIL水平及生活质量。结果:与治疗前比较,治疗后两组心功能和血脂水平均有显著改善,血清TNF-α和TRAIL水平均显著降低(P均=0.001);且与阿托伐他汀组比较,联合治疗组治疗后心排血量[(4.1±0.8)L/min比(4.9±0.6)L/min]、心脏指数[(3.9±0.6) L·min~(-1)·m~(-2)比(4.2±0.7) L·min~(-1)·m~(-2)]、左室射血分数[(52.4±1.6)%比(59.6±1.5)%]、血清高密度脂蛋白-胆固醇[(1.5±0.4) mmol/L比(1.9±0.5) mmol/L]水平及生活质量[(6.2±0.8)分比(7.1±1.1)分]均显著提高,左室舒张末期内径[(5.4±0.6)cm比(5.0±0.7)cm]、血清总胆固醇[(4.1±0.7) mmol/L比(3.7±0.9) mmol/L]、甘油三酯[(1.4±0.6) mmol/L比(1.1±0.5) mmol/L]、低密度脂蛋白-胆固醇[(2.9±0.8) mmol/L比(2.4±0.8) mmol/L]、TNF-α[(52.1±12.6)ng/L比(41.3±14.2)ng/L]和TRAIL [(44.7±24.1) pg/ml比(34.1±26.6) pg/ml]水平显著降低(P<0.05或<0.01)。结论:复方丹参滴丸联合阿伐他汀治疗冠心病并高脂血症患者,可显著改善心功能、降低血脂水平,提高生活质量。
Objective: To explore therapeutic effect of compound Danshen dripping pills combined atorvastatin on coronary heart disease(CHD) complicated hyperlipidemia and its influence on serum level of tumor necrosis factor-related apoptosis inducing ligand(TRAIL). Methods:A total of 109 CHD patients with hyperlipidemia treated in our department of cardiology were collected, randomly divided into atorvastatin group(n=57) and combined treatment group(n=52, received atorvastatin combined compound Danshen dripping pills), both groups were continuously treated for three months. Cardiac function, levels of blood lipids, serum tumor necrosis factor(TNF)-α, TRAIL and quality of life(QOL) were measured and compared between two groups before and after treatment. Results:Compared with before treatment, there were significant improvements in cardiac function and blood lipid levels, and significant reductions in serum levels of TNF-α and TRAIL in two groups after treatment, P=0.001 all; compared with atorvastatin group after treatment, there were significant rise in cardiac output [(4.1±0.8)L/min vs.(4.9±0.6)L/min], cardiac index [(3.9±0.6) L·min~(-1)·m~(-2) vs.(4.2±0.7) L·min~(-1)·m~(-2)], LVEF [(52.4±1.6)% vs.(59.6±1.5)%], serum HDL-C [(1.5±0.4) mmol/L vs.(1.9±0.5) mmol/L]and QOL [(6.2±0.8) scores vs.(7.1±1.1) scores], and significant reductions in LVEDd [(5.4±0.6)cm vs.(5.0±0.7)cm], serum levels of TC [(4.1±0.7) mmol/L vs.(3.7±0.9) mmol/L], TG [(1.4±0.6) mmol/L vs.(1.1±0.5) mmol/L], LDL-C [(2.9±0.8) mmol/L vs.(2.4±0.8) mmol/L], TNF-α[(52.1±12.6)ng/L vs.(41.3±14.2)ng/L]and TRAIL [(44.7±24.1) pg/ml vs.(34.1±26.6) pg/ml]in combined treatment group, P<0.05 or <0.01. Conclusion:Compound Danshen dripping pills combined atorvastatin can significantly improve heart function, reduce blood lipid levels and improve quality of life in CHD patients with hyperlipidemia.
引文
[1]朱春频.他汀类药物治疗冠心病合并高脂血症的效果分析[J].中西医结合心脑血管病杂志,2012,10(2):144.
[2]王丽美,许军芳,陈文静,王锐霞,张娜.复方丹参滴丸联合阿托伐他汀治疗冠心病并高脂血症的疗效分析[J].中国临床保健杂志,2015,14(5):489-492.
[3]彭艳.复方丹参滴丸联合瑞舒伐他汀治疗冠心病合并高脂血症患者的临床疗效[J].世界最新医学信息文摘,2015,15(24):138-139.
[4]刘芳芳.肿瘤坏死因子相关凋亡诱导配体及其受体DR5对动脉粥样硬化斑块形成的影响[D].济南:山东大学,2014.
[5]齐玲,赵东海,王玮瑶,等.Caspase-8和Bcl-2在脑肿瘤干细胞肿瘤坏死因子相关凋亡诱导配体耐药中的作用研究[J].中国药学杂志,2015,50(2):152-156.
[6]钱茜.阿托伐他汀治疗老年冠心病合并高脂血症临床研究[J].中国现代药物应用,2013,7(10):72-73.
[7]宋勇宏.阿托伐他汀在老年冠心病合并高脂血症中的应用分析[J].中国当代医药,2013,20(15):65-66.
[8]吴法令.阿托伐他汀治疗老年冠心病合并高脂血症的临床分析[J].现代诊断与治疗,2013,24(3):627-628.
[9]陈树彤,史培杰,黄电波,等.复方丹参滴丸治疗冠心病合并高脂血症疗效观察[C].复方丹参滴丸美国FDAII期临床试验结果报告暨第四届学术研讨会论文集.2010:183-185.
[10]刘清安.辛伐他汀(舒降之)联合复方丹参滴丸治疗冠心病合并高脂血症102例临床分析[J].医学理论与实践,2012,25(13):1583-1584.
[11]许玲.复方丹参滴丸联合瑞舒伐他汀治疗冠心病合并高脂血症患者的临床疗效[J].中国循证心血管医学杂志,2014,7(1):99-101.
[12]纪佳.复方丹参滴丸对高血脂患者血液流变学的影响[J].中国当代医药,2013,6(8):117-118,120.
[13]林大梁,林先锋,袁小兰.复方丹参滴丸治疗冠心病的临床分析[J].数理医药学杂志,2013,26(1):82-83.
[14]任满意,张运,隋树建,等.肿瘤坏死因子相关的凋亡诱导配体及其死亡受体5与急性冠状动脉综合征的关系[J].中国动脉硬化杂志,2007,15(11):842-846.
[15]刘利宁.急性脑梗死患者血清TRAIL、OPG测定及其临床意义的研究[D].兰州:兰州大学,2011.
[16]白景瑞.清热解毒方与凉血活血方防治术后腹腔粘连的实验研究[D].天津:天津医科大学,2016.
[17]李响,吴振起,马雪涛,等.注射用血栓通对大鼠血管内皮细胞凋亡机制的影响[J].中华中医药杂志,2010,25(7):1137-1139.
[18]华新宇,王晓兰,康美清,等.三七总皂苷对慢性心力衰竭患者心功能及血浆细胞凋亡相关因子的影响[J].中国中医急症,2014,23(12):2368-2370.
[19]Schoppet M,Sattler AM,Schaefer JR,et al.Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis[J].Atherosclerosis,2006,184(2):446-447.
[20]Morel J,Audo R,Hahne M,et al.Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol3kinase/Akt[J].J Biol Chem,2005,280(16):15709-15718.
[21]王素云,王海芸,黄晓燕,等.阿托伐他汀对大鼠缺血心肌TRAIL表达及细胞凋亡的影响[J].温州医学院学报,2012,42(4):317-321.
